Choose Your Country or Region

Durvalumab (anti-PD-L1)

Synonyms: MEDI4736

Catalog No.A2013 Purity: 99.77%

Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

Click to purchase the isotype control of Durvalumab (anti-PD-L1)

Selleck's Durvalumab (anti-PD-L1) has been cited by 12 Publications

1 Customer Review

Purity & Quality Control

Batch: Purity: 99.77% Protein concentration: 5.89mg/ml Endotoxin Level: ≤1 EU/mg

99.77

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description

Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

Features

Human IgG1

Targets

PD-L1/CD80 ^[1] (HTRF assay)	PD-1/PD-L1 interaction ^[1] (HTRF assay)
0.04 nM	0.1 nM

In Vitro
In vitro	The labeled radioligand shows good affinity to high PD-L1 expression cells and could be blocked with excess unlabeled intact durvalumab.^[1]
Cell Research:	The A549 and H460 cells were cultured in six-well plates (~106 cells/well) and divided into two groups. All of the wells were incubated with 5% BSA for blocking nonspecific binding. Group A was presaturated with 100-fold excess of unlabeled durvalumab to block the binding of ¹²⁴I-Durva-F(ab′)₂, and group B had only the medium added. After 30 min, 2 nM of ¹²⁴I-Durva-F(ab′)₂ was added to each group and incubated for 1 h at 37 °C in a cell incubator. After supernatant collection, the cells were lysed using 2 M of NaOH.

In Vitro

In vitro

The labeled radioligand shows good affinity to high PD-L1 expression cells and could be blocked with excess unlabeled intact durvalumab.^[1]

Cell Research:

The A549 and H460 cells were cultured in six-well plates (~106 cells/well) and divided into two groups. All of the wells were incubated with 5% BSA for blocking nonspecific binding. Group A was presaturated with 100-fold excess of unlabeled durvalumab to block the binding of ¹²⁴I-Durva-F(ab′)₂, and group B had only the medium added. After 30 min, 2 nM of ¹²⁴I-Durva-F(ab′)₂ was added to each group and incubated for 1 h at 37 °C in a cell incubator. After supernatant collection, the cells were lysed using 2 M of NaOH.

In Vivo
In vivo	The peak tumor uptake of ¹²⁴I-Durva-F(ab’)₂ was close to ¹²⁴I-Durva, but much earlier (5.29±0.42% ID/g for 124I-Durva-F(ab’)₂ at 12 h vs 5.18±0.73% ID/g for ¹²⁴I-Durva at 48 h). Compared with ¹²⁴I-Durva, an accelerated blood clearance was observed for ¹²⁴I-Durva-F(ab’)₂, allowing for a higher tumor-to-background ratio.^[1]
Animal Research	Animal Models: H460 and A549 tumor-bearing mice Dosages: 20 μCi Administration: i.v.

References
[1] Cheng Y, et al. Mol Pharm. 2022 Mar 4.

References

[1] Cheng Y, et al. Mol Pharm. 2022 Mar 4.

Product Details

CAS No.	1428935-60-7
Isotype	Human IgG1
Source	CHO cells
Formulation	PBS buffer, pH 7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.